

European Journal of Chemistry

Journal homepage: www.eurjchem.com



Synthesis of some novel Schiff bases containing 1,2,4-triazole ring

Akbar Mobinikhaledia,*, Naser Foroughifara,b, Mansooreh Khanpoura and Sattar Ebrahimic

^a Department of Chemistry, Faculty of Sciences, Arak University, Arak, IR-38156, Iran

^b Faculty of Chemistry, Islamic Azad University, North Tehran Branch, IR-19395, Iran

^c Department of Chemistry, Faculty of Sciences, Islamic Azad University Malayer, Malayer, IR-65718-117, Iran

*Corresponding author at: Department of Chemistry, Faculty of Sciences, Arak University, Arak, IR-38156, Iran. Tel.: +98.861.2777225; fax: +98.861.2774031. E-mail address: akbar mobini@yahoo.com (A. Mobinikhaledi).

ARTICLE INFORMATION

Received: 7 February 2010 Received in revised form: 26 February 2010 Accepted: 8 March 2010 Online: 31 March 2010

KEYWORDS

1,2,4-triazole Schiff bases Acetohydrazide Synthesis Heterocyclic compounds

1. Introduction

The chemistry of 1,2,4-triazoles and their fused heterocyclic derivatives have received considerable attention owing to their synthetic and effective biological importance. For example, a large number of 1,2,4-triazoles have been incorporated into a wide variety of therapeutically interesting drug candidates including anti-inflammatory [1,2], antiviral [3], analgesic [4], antimicrobial [5-7], anticonvulsant [8] and antidepressant activities [9]. The hybrid molecules composed of the combination of a heterocyclic ring and a Schiff base may exert potentially biological activities. Some Schiff bases bearing triazoles have been reported to be used as drugs with considerable biological activities [10-16].

In view of this report and also due to the connections of our studies on the synthesis of substituted triazoles [17,18], we turned our attention to synthesis of some new 1,2,4-triazole derivatives and their related Schiff bases obtained from the reaction of 2-(4-allyl-5-(pyridine-4-yl)-4H-1,2,4-triazol-3-ylthio)acetohydrazide, **5**, with various aldehydes (Scheme 1).

2. Experimental

2.1. Instrumentation

Purity of the compounds were checked by thin layer chromatography (TLC) using $C_2H_5OH:n$ -hexane (1:1) as an eluent. IR spectra were prepared on the Mattson Galaxy series FT-IR 5000 spectrophotometer using KBr discs. NMR spectra were recorded on Bruker spectrophotometer (300 MHz) in DMSO- d_6 or CDCl₃ using TMS as an internal standard. Microanalyses were performed by the Elemental Analyzer (Vario EL III) at the Arak University.

ABSTRACT

4-Allyl-5-piridine-4-yl-4H-1,2,4-triazole-3-thiol was prepared under facile condition via the formation of 2-isonicotinoyl-*N*-allylhydrazinecarbothioamide. In addition, ethyl[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3-yl)thio]acetate was synthesized via the reaction of 4-allyl-5-piridine-4-yl-4H-1,2,4-triazole-3-thiol with ethyl chloroacetate. 2-[(4-Allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3-yl)thio]acetohydrazide obtained by using ethyl[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3-yl)thio]acetate as a precursor by two steps, was converted to Schiff base derivatives, 6a-j. All synthesized compounds were characterized by elemental analyses, IR spectroscopy, ¹H NMR and ¹³C NMR spectroscopy. The *cis/trans* conformers of *E* isomer were present in DMSO solution of compounds 6a-j.

2.2. Synthesis of 2-isonicotinoyl-N-allylhydrazinecarbothio amide, 2

A mixture of isonicotinic acid hydrazide, **1**, (0.01 mol, 1.3700 g) and allyl isothiocyanate (0.01 mol, 0.9900 g) was refluxed in ethanol (30 mL) for 2 h. After cooling, the formed product was collected by filtration and recrystallized from ethanol to give thiosemicarbazide, **2**. Yield: 95% (2.2420 g), M.p.: 227-230 °C. IR (KBr, v, cm⁻¹): 3070 (aromatic CH stretch.), 3200, 3259 (NH), 2928 (C-H), 1678 (C=O), 1554, 1440 (C=C ring stretch.), 1352 (C=S). ¹H NMR (DMSO-*d*₆, δ , ppm): 10.68 (s, 1H, NH), 9.49 (s, 1H, NH), 8.75-8.77 (d, 2H, *J*=4.6 Hz, Ar*H*), 8.39 (s, 1H, NH), 7.81-7.89 (d, 2H, *J*=4.7 Hz, Ar*H*), 5.76-5.88 (m, 1H, C=CH-C), 5.03-5.16 (m, 2H, CH₂=C-C), 4.11 (s, 2H, CH₂). ¹³C NMR (DMSO-*d*₆, δ , ppm): 46.4, 115.7, 122.1, 135.4, 140.0, 150.6, 164.9, 182.2.

2.3. Synthesis of 4-allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3thiol, 3

A solution of thiosemicarbazide, **2**, (0.005 mol, 1.1800 g) in 2N NaOH (10 mL) was refluxed for 3 h. The resulting solution was cooled to room temperature and acidified (pH=3) with 2N HCl. The precipitate was filtered and washed with water. The compound obtained was dried and crystallized from DMF:C₂H₅OH (1:2) to give compound **3**. Yield (0.9920 g) 91%. M.p.: 219-221 °C. IR (KBr, v, cm⁻¹): 3070 (aromatic CH stretch.), 2733 (SH), 1568, 1438 (C=C ring stretch). ¹H NMR (DMSO-*d*₆, δ, ppm): 14.27 (s, 1H, SH), 8.76 (d, 2H, *J*= 4.8 Hz, Ar*H*), 7.71 (d, 2H, *J*= 4.8 Hz, Ar*H*), 5.80-5.92 (m, 1H, C=C*H*-C), 5.12-5.16 (m, 1H, *CH*₂=C-C), 4.81-4.89 (m, 1H, *CH*₂=C-C), 4.79 (br, 2H, *CH*₂). Anal. Calcd. for C₁₀H₁₀N₄S: C, 55.02; H, 4.69; N, 25.67; S, 14.69. Found: C, 54.82; H, 4.51; N, 25.44; S, 14.44 %.



Scheme 1. Synthetic pathway for preparation of Schiff bases 6a-j.

2.4. Synthesis ethyl[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triazo le-3-yl)thio]acetate, 4

To a solution of compound 3 (0.003 mol, 0.6500 g) in absolute ethanol (20 mL), ethyl chloroacetate (0.006 mol, 0.7320 g) was added. The mixture was refluxed under stirring for 30 min in the presence of KOH (0.003 mol, 0.1680 g). Then, the solvent was removed under reduced pressure to give the solid product. The crude product was recrystallized from H₂O:C₂H₅OH (1:1) to give compound **4**. Yield (0.6617 g) 73%. M.p.: 143-145 °C. IR (KBr, v, cm⁻¹): 3069 (aromatic CH stretch.), 2968 (C-H), 1732 (C=O), 1602 (C=N), 1199 (C-O). ¹H NMR (CDCl₃, δ, ppm): 8.78 (d, 2H, J=4.8 Hz, ArH), 7.68 (d, 2H, J=4.8 Hz, ArH), 5.88-6.12 (m, 1H, C=CH-C), (m, 1H, CH₂), 5.39-5.43 (m, 1H, CH2=C-C), 5.01-5.07 (m, 1H, CH2=C-C), 4.72 (br, 2H, C=C-CH2), 4.22 (q, 2H, J=7.1 Hz, CH2), 4.14 (s, 2H, SCH2), 1.30 (t, 3H, J=7.0 Hz, CH₃). ¹³C NMR (CDCl₃, δ, ppm): 14.0, 35.2, 47.0, 62.0, 18.4, 122.0, 131.0, 134.4, 150.3, 152.0, 153.5, 168.0. Anal. Calcd. for C14H16N4O2S: C, 55.25; H, 5.30; N, 18.41; S, 10.53. Found: C, 55.02; H, 5.22; N, 18.20; S, 10.34 %.

2.5. Synthesis of 2-[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triazo le-3-yl)thio]acetohydrazide, 5

80% hydrazine hydrate (0.003 mol, 0.15 g) was added to **4** (0.002 mol, 0.6080 g) in ethanol (10 mL) in drops and refluxed for 2 h. The solvent was then removed under reduced pressure and a solid was obtained. Next, the precipitate was filtered and recrystallized from CCl₄ to give the pure acetohydrazide **5**. Yield (0.4930 g) 85%. M.p.: 143-145 °C. IR (KBr, ν, cm⁻¹): 3286 3196 (NH₂), 3234, (NH), 3024 (aromatic CH stretch.), 1672 (C=O), 1604 (C=N), 1547, 1456 (C=C ring stretch.). ¹H NMR (CDCl₃, δ, ppm): 8.78-8.80 (d, d, 2H, *J*=4.5 Hz, 1.4 Hz, Ar*H*), 7.58-7.60 (d, d, 2H, *J*=4.5 Hz, 1.5 Hz, Ar*H*), 5.92-6.01 (m, 1H, C=CH-C), 5.40-5.44 (m, 1H, CH₂=C-C), 5.04-5.10 (m, 1H, CH₂=C-C), 4.62 (br, 2H, CH₂), 3.96 (s, 2H, SCH₂). Anal. Calcd. for C₁₂H₁₄N₆O₂S: C, 49.64; H, 4.86; N, 28.95; S, 11.04. Found: C, 49.49; H, 4.75; N, 28.74; S, 10.81 %.

2.6. General procedure for the synthesis of compounds 6a-j

A solution of acetohydrazide, **5**, (0.0006 mol, 0.1740 g) in ethanol (7 mL), the appropriate aldehyde (0.0006 mol) and 4-5

drops of glacial acetic acid (as a catalyst) was refluxed for a predetermined time frame (Table 1). The resultant was allowed to cool and poured into cold water (15-20 mL). The solid was collected by filtration and recrystallized from ethanol to give the pure acetohydrazide **6a-j**.

N'-benzylidene-2-[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triaz

ole-3-yl)thio]acetohydrazide, 6a: IR (KBr, ν , cm⁻¹): 3203 (NH), 3051 (aromatic CH stretch.), 1689 (C=O), 1608 (C=N), 1577, 1456 (C=C ring stretch.), 761 (C-S-C). ¹H NMR (DMSO- d_{c} , δ , ppm): 11.82 and 11.71 (s, 1H, NH, trans/cis conformers), 8.72-8.76 (m, 2H, ArH), 8.19 and 8.02 (s, 1H, N=CH, trans/cis conformers), 7.61-7.70 (m, 4H, ArH), 7.40-7.42 (m, 3H, ArH), 5.97-6.03 (m, 1H, C=CH-C), 5.23-5.27 (m, 1H, CH₂=C-C), 4.83-4.89 (m, 1H, CH₂=C-C), 4.77 (d, 2H, J=1.8 Hz, CH₂), 4.53 and 4.15 (s, 2H, SCH₂, trans/cis conformers). Anal. Calcd. for C₁₉H₁₈N₆OS: C, 60.30; H, 4.79; N, 22.21; S, 8.47. Found: C, 60.11; H, 4.71; N, 22.09; S, 8.38 %.

N'-4-Nitrobenzylidene-2-[(4-allyl-5-pyridine-4-yl-4H-1,2,

4-triazole-3-yl)thio]acetohydrazide, 6b: IR (KBr, ν, cm⁻¹): 3080 (aromatic CH stretch.), 1679 (C=O), 1601 (C=N), 1450, 1516 (C=C ring stretch.), 1342, 1500 (NO₂). ¹H NMR (DMSO-*d₆*, δ, ppm): 12.01 (br, 1H, N*H*), 8.71-8.76 (m, 2H, Ar*H*), 8.25-8.31 (m, 2H, Ar*H*), 8.10 (s, 1H, N=C*H*), 7.92-7.99 (m, 2H, Ar*H*), 7.60-7.67 (m, 2H, Ar*H*), 5.96-6.08 (m, 1H, C=C*H*-C), 5.24-5.28 (m, 1H, C*H*₂=C-C), 4.79-4.80 (m, 1H, C*H*₂=C-C), 4.79 (br, 2H, C*H*₂), 4.55 and 4.17 (s, 2H, SC*H*₂, *trans/cis* conformers). Anal. Calcd. for C₁₉H₁₇N₇O₃S: C, 53.89; H, 4.05; N, 23.15; S, 7.57. Found: C, 53.61; H, 3.97; N, 22.97; S, 7.41 %.

N'-3-Nitrobenzylidene-2-[(4-allyl-5-pyridine-4-yl-4H-1,2,

4-triazole-3-yl)thio]acetohydrazide, 6c: IR (KBr, v, cm⁻¹): 3212 (NH), 3074 (aromatic CH stretch.), 1689 (C=O), 1608 (C=N), 1352-1529 (N=O). ¹H NMR (DMSO- d_6 , δ , ppm): 12.06 and 11.93 (s, 1H, NH, *trans/cis* conformers), 8.72-8.76 (m, 2H, ArH), 8.53 and 8.47 (s, 1H, N=CH, *trans/cis* conformers), 8.12-8.33(m, 3H, ArH), 7.60-7.75 (m, 3H, ArH), 6.00 (br, 1H, C=CH-C), 5.25-5.28 (m, 1H, CH₂=C-C), 4.83-4.89 (m, 1H, CH₂=C-C), 4.79 (br, 2H, CH₂), 4.55 and 4.17 (s, 2H, SCH₂, *trans/cis* conformers). Anal. Calcd. for C₁₉H₁₇N₇O₃S: C, 53.89; H, 4.05; N, 23.15; S, 7.57. Found: C, 53.57; H, 3.93; N, 23.01; S, 7.38 %.

N⁻2-Hydroxybenzylidene-2-[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3-yl)thio]acetohydrazide, 6d: IR (KBr, v, cm⁻): 3435 (0-H), 3213 (NH), 3047 (aromatic CH stretch.), 2982 (C-H), 1685 (C=O), 1608 (C=N); ¹H NMR (DMSO- d_6 , δ , ppm): 12.98 and 11.62 (s, 1H, NH, *trans/cis* conformers), 10.95 and 10.06 (s, 1H, OH, *trans/cis* conformers), 8.73-8.76 (d, d, 2H, *J*=4.3 Hz, 1.5 Hz, ArH), 8.32 and 8.42 (s, 1H, N=CH, *trans/cis* conformers), 7.21-7.32 (m, 1H, ArH), 7.54-7.67 (m, 3H, ArH), 6.85-6.92 (m, 2H, ArH), 5.98-6.09 (m, 1H, C=CH-C), 5.24-5.30 (m, 1H, CH₂=C-C), 4.84-4.90 (d, d, 1H, *J*=17.3 Hz, 3.4 Hz, CH₂=C-C), 4.77 (br, 2H, CH₂), 4.51 and 4.14 (s, 2H, SCH₂, *trans/cis* conformers). Anal. Calcd. for C₁₉H₁₈N₆O₂S: C, 57.85; H, 4.60; N, 21.31; S, 8.13. Found: C, 57.54; H, 4.51; N, 21.10; S, 7.95 %.

N'-5-Bromo-2-hydroxybenzylidene-2-[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3-yl)thio]acetohydrazide, 6e: IR (KBr, ν, cm⁻¹): 3431 (0-H), 3175 (N-H), 2978 (C-H), 1674 (C=O), 1606 (C=N). ¹H NMR (DMSO-d₆, δ, ppm): 11.54 and 11.47 (s, 1H, *NH, trans/cis* conformers), 9.29 (s, 1H, OH), 9.43 (s, 1H, OH), 8.74 (br, 2H, ArH), 7.88 and 7.83 (s, 1H, N=CH, *trans/cis* conformers), 7.62-7.67 (m, 2H, ArH), 7.15 (br, 1H, ArH), 6.87-6.92 (m, 1H, ArH), 6.76 (br, 1H, ArH), 5.96-6.06 (m, 1H, C=CH-C), 5.23-5.27 (m, 1H, CH₂=C-C), 4.83-4.89 (m, 1H, CH₂=C-C), 4.77 (br, 2H, CH₂), 4.50 and 4.09 (s, 2H, SCH₂, *trans/cis* conformers). Anal. Calcd. for C₁₉H₁₈N₆BrO₂S: C, 48.21; H, 3.62; N, 17.75; S, 6.77. Found: C, 47.96; H, 3.55; N, 17.41; S, 6.59 %.

N'-3,4-Dihydroxybenzylidene-2-[(4-allyl-5-pyridine-4-yl-

4H-1,2,4-triazole-3-yl)thio]acetohydrazide, 6f: IR (KBr, v, cm⁻¹): 3429 (OH), 3178 (NH), 3033 (aromatic CH stretch.), 1674 (C=O), 1605 (C=N). 729 (C-S-C), ¹H NMR (DMSO-*d*₆, δ , ppm): 12.06 and 11.68 (s, 1H, N*H*, *trans/cis* conformers), 8.73-8.76 (m, 2H, Ar*H*), 11.03 and 10.40 (s, 1H, O*H*, *trans/cis* conformers), 8.38 and 8.24 (s, 1H, N=C*H*, *trans/cis* conformers), 8.38 and 8.24 (s, 1H, N=C*H*, *trans/cis* conformers), 7.77 (br, 1H, Ar*H*), 7.60-7.66 (m, 2H, Ar*H*), 7.37-7.43 (m, 1H, Ar*H*), 6.84-6.90 (m, 1H, Ar*H*), 5.98-6.05 (m, 1H, C=C*H*-C), 5.24-5.28 (m, 1H, C*H*₂=C-C), 4.85-4.90 (m, 1H, C*H*₂=C-C), 4.78 (br, 2H, C*H*₂), 4.50 and 4.13 (s, 2H, SCH₂, *trans/cis* conformers). Anal. Calcd. for C₁₉H₁₈N₆O₃S: C, 55.60; H, 4.42; N, 20.48; S, 7.81. Found: C, 55.31; H, 4.34; N, 20.32; S, 7.56 %.

N'-4-Methylbenzylidene-2-[(4-allyl-5-pyridine-4-yl-4H-1,

2,4-triazole-3-yl)thio]acetohydrazide, 6g: IR (KBr, v, cm⁻¹): 3205 (NH), 3047 (aromatic CH stretch.), 2931 (C-H), 1697 (C=O), 1606 (C=N), 1375, 1450 (CH₃). ¹H NMR (DMSO-*d*₆, δ , ppm): 11.73 and 11.63 (s, 1H, N*H*, *trans/cis*, conformers), 8.75 (d, 2H, *J*=4.8 Hz, Ar*H*), 7.97 and 8.15 (s, 1H, N=C*H*, *trans/cis* conformers), 7.54-7.67 (m, 4H, Ar*H*), 7.22-7.27 (m, 2H, Ar*H*), 5.97-6.07 (m, 1H, C=C*H*-C), 5.23-5.27 (m, 1H, CH₂=C-C), 4.77-4.88 (m, 1H, C*H*₂=C-C), 4.55 (br, 2H, C*H*₂), 4.12 and 4.50 (s, 2H, SC*H*₂, *trans/cis* conformers), 2.32 (s, 3H, CH₃). Anal. Calcd. for C₂₀H₂₀N₆OS: C, 61.20; H, 5.14; N, 21.41; S, 8.17. Found: C, 61.00; H, 5.30; N, 21.11; S, 8.32 %.

N'-3,4-Dimethoxylbenzylidene-2-[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3-yl)thio]acetohydrazide, 6h

IR (KBr, v, cm⁻¹): 3205 (NH), 3050 (aromatic CH stretch.), 2962 (C-H), 1680 (C=O), 1602 (C=N), 1512, 1438 (C=C ring stretch.). ¹H NMR (DMSO- d_6 , δ , ppm): 11.95 and 11.59 (s, 1H, NH, *trans/cis* conformers), 8.72-8.76 (br, 2H, ArH), 8.11 and 7.93 (s, 1H, N=CH, *trans/cis* conformers), 7.59 (s, 1H, ArH), 7.19 (t, 1H, *J*=8.5 Hz, ArH), 6.99 (t, 1H, *J*=8.5 Hz, ArH), 5.97-6.06 (m, 1H, C=CH-C), 5.24 (d, 1H, *J*=10.5 Hz, CH₂=C-C), 4.82-4.90 (m, 1H, CH₂=C-C), 4.77 (br, 2H, CH₂), 4.48 and 4.11 (s, 2H, SCH₂, *trans/cis* conformers), 3.79 (s, 6H, 20CH₃). Anal. Calcd. for C₂₁H₂₂N₆O₃S: C, 57.52; H, 5.06; N, 19.17; S, 7.31. Found: C, 57.82; H, 5.03; N, 19.00; S, 7.61 %.

N'-4-Chlorobenzylidene-2-[(4-allyl-5-pyridine-4-yl-4H-1,

2,4-triazole-3-yl)thio]acetohydrazide, 6i: IR (KBr, v, cm⁻¹): 3205 (NH), 3040 (aromatic CH stretch.), 1697 (C=O), 1606 (C=N), 1547, 1440 (C=C ring stretch.), 827 (C-Cl). ¹H NMR (DMSO- d_6 , δ , ppm): 11.86 and 11.75 (s, 1H, NH, *trans/cis* conformers), 8.73-8.76 (br, 2H, ArH), 8.19 and 8.00 (s, 1H, N=CH, *trans/cis* conformers), 7.60-7.74 (m, 4H, ArH), 7.47-7.52 (m, 2H, ArH), 5.98-6.07 (m, 1H, C=CH-C), 5.24-5.27 (m, 1H, CH₂=C-C), 4.83-4.88 (m, 1H, CH₂=C-C), 4.77 (br, 2H, CH₂), 4.53 and 4.13 (s, 2H, SCH₂, *trans/cis* conformers). Anal. Calcd. for C₁₉H₁₇ClN₆OS: C, 55.27; H, 4.15; N, 20.35; S, 7.77. Found: C, 54.95; H, 4.31; N, 20.00; S, 7.40 %.

N'-4-Bromobenzylidene-2-[(4-allyl-5-pyridine-4-yl-4H-1,

2,4-triazole-3-yl)thio]acetohydrazide, **6j**: IR (KBr, ν, cm⁻¹): 3207 (NH), 3033 (aromatic CH stretch.), 1686 (C=O), 1606 (C=N). ¹H NMR (DMSO-*d*₆, δ, ppm): 11.85 and 11.74 (s, 1H, N*H*, *trans/cis* conformers), 8.75 (d, 2H, *J*=5.2 Hz, Ar*H*), 8.17 and 7.98 (s, 1H, N=C*H*, *trans/cis* conformers), 7.60-7.67 (m, 6H, Ar*H*), 6.01-6.07 (m, 1H, C=C*H*-C), 5.24-5.27 (m, 1H, CH₂=C-C), 4.77-4.89 (m, 1H, CH₂=C-C), 4.77 (br, 2H, CH₂), 4.51 and 4.13 (s, 2H, SCH₂, *trans/cis* conformers). Anal. Calcd. for C₁₉H₁₇BrN₆OS: C, 49.90; H, 3.75; N, 17.47; S, 7.01. Found: C, 49.70; H, 3.66; N, 17.31; S, 6.82 %.

3. Results and Discussion

In continuation of our efforts to develop the synthesis of the new fused heterocyclic and Schiff bases [19-21] we report herein, a simple and efficient method for the synthesis of some novel Schiff bases containing 1,2,4-triazole ring. Our synthetic approaches are depicted in Scheme 1. Initial compound was prepared from available isonicotinic acid hydrazide, 1. 2-Isonicotinovl-*N*-allylhydrazinecarbothioamide, **2**, was prepared by reaction of compound **1** with allylisothiocyanate in ethanol. The cyclization of compound 2 in the presence of sodium hydroxide resulted in the formation of 4-allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3-thiol, 3. The reaction of triazole 3 with ethyl chloroacetate in the presence of potassium hydroxide produced ethyl[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3-yl)thio]aceta te 4, which then converted to 2-[(4-allyl-5-pyridine-4-yl-4H-1,2,4-triazole-3-yl)thio]acetohydrazide, 5, via the reaction with hydrazine hydrate. The treatment of acetohydrazide 5 with several aldehydes gave N'-substitue-benzylidene-2-[(4-allyl-5pyridine-4-yl-4H-1,2,4-triazole-3-yl)thio]acetohydrazide, 6a-i, (Scheme 1). The results are shown in Table 1. The compounds having aryliden-hydrazid structure may exist as E/Zgeometrical isomers about CH=N double bond and cis/trans amide conformers (Scheme 2) [22-24]. According to the literature [23,24], compounds containing imine bonds are present in higher percentage in dimethyl-d₆ sulfoxide solution in the form of geometrical *E* isomer about C=N double bond. The Z isomer can be stabilized in less polar solvent by an intramolecular hydrogen bond. In the present study, the spectral data were obtained in DMSO-d₆ and no signal belonging to the Z isomer was observed. On the other hand, the cis/trans conformers of the E isomer were present in DMSO solution of compounds 6a-j.

Table 1	. Synthesized Schiff bases	6a-j
---------	----------------------------	------

Compound	Ar*	Time (h)	M.p. (°C)	Yield (%)
6a	C ₆ H ₅	6	102-104	62
6b	4-(NO ₂)C ₆ H ₄	8	201-203	55
6c	3-(NO ₂)C ₆ H ₄	7	164-165	54
6d	2-(OH)C ₆ H ₄	1	160-161	83
6e	5-(Br),2-(OH)C ₆ H ₃	0.5	213-215	75
6f	3,4-(OH) ₂ C ₆ H ₃	0.5	234-236	73
6g	4-(CH ₃)C ₆ H ₄	4	119-122	81
6h	3,4-(OCH ₃) ₂ C ₆ H ₃	3	248-251	74
6i	4-(Cl)C ₆ H ₄	3	128-130	77
6ј	$4-(Br)C_6H_4$	2	183-185	68

*Scheme 1.



Scheme 2. E/Z Geometrical isomers and cis/trans conformers of 6a-j.

The structures of the synthesized compounds were determined on the basis of spectral data analysis including IR, ¹H NMR and ¹³C NMR. The ¹H NMR spectrum of compound 2 showed two characteristic absorptions (singlet at δ =9.49 ppm and δ =10.68 ppm) attributed to the NH groups, which were disappeared by the formation of the triazole 3. In the ¹H NMR spectrum of compound 4, additional signals derived from the ester group were observed at 1.30 (OCH₂CH₃), 4.14 (SCH₂) and 4.22 OCH₂CH₃) ppm. The ¹H NMR spectra of **6a-j** displayed additional signals due to the aromatic ring derived from aldehyde moiety at the aromatic region, while the signal belonging to the NH₂ group of hydrazide structure was not appeared. In the ¹H NMR spectra of compounds 6a-j two signals each belonging to the SCH₂, N=CH and NH groups of *cis* and trans conformers were observed between 3.98-4.55, 7.97-9.85 and 11.47-12.00 ppm, respectively.

Acknowledgement

The authors gratefully acknowledge the financial support from the Research Council of Arak University.

References

- Unangst, P. C.; Shurum, G. P.; Connor, D. T.; Dyer, R. D.; Schrier, D. J. J. [1]. Med. Chem. 1992, 35, 3691-3698.
- Mullican, M. D.; Wilson, M. W.; Connor, D. T.; Kostlan, C. R.; Schrier, D. [2]. J.; Dyer, R. D. J. Med. Chem. 1993, 36, 1090-1099.
- Jones, D. H.; Slack, R.; Squires, S.; Wooldridge, K. R. H. J. Med. Chem. [3]. 1965.8.676-680.
- Sughen, J. K.; Yoloye, T. Pharm. Acta Helv. 1978, 58, 64-68. [4].
- Shams, El-Dine Sh A.; Hazzaa, A. A. B. Pharmazie, 1974, 29, 761-768. [5]. Misato, T.; Ko, K.; Honma, Y.; Konno, K.; Taniyama, E. JP 77-25028 [6].
- (A01N9/12), Chem. Abstr. 1977, 87, 147054a Cansız, A.; Servi, S.; Koparır, M.; Altıntas, M.; Dığrak, M. J. Chem. Soc. Pak. [7].
- 2001, 23, 237-239 [8]. Stillings, M. R. Welbourn, A. P.; Walter, D. S. J. Med. Chem. 1986, 29,
- 2280-2284. [9]. Kane, J. M.; Dudley, M. W.; Sorensen, S. M.; Miller, F. P. J. Med. Chem.
- 1988. 31. 1253-1258. [10]. Chaha, V. K.; Ranwa, N. S.; Dadheech, P. K. J. Phytol. Res. 1998, 11, 201-
- 202
- Sakata, M.; Shirakawa, Y.; Kamata, N.; Hiroshino, Y. S.; Jie, O. Y. J. [11]. Heterocyclic. Chem. 2000, 37, 269-271.
- [12]. Nadkarni, B. A.; Kamat, V. R.; Khadse, B. G. Arzneim. Force 2001, 51, 569-573.

- [13]. Holla, B. S.; Akberali, P. M.; Shivananda, M. K. Farmaco 2001, 56, 919-927
- [14]. Hui, X. P.; Zhang, Y.; Xu, P. F.; Wang, Q.; Zhang, Q.; Zhang, Z. Y. Chin. J. Org. Chem. 2005, 25, 700-704.
- [15]. B. S.; Rao, B. S.; Sarojini, B. K.; Akberali, P. M.; Kumari, N. S.; Eur. J. Med. Chem. 2006, 41, 657-663.
- [16]. Zhou, S. N.; Zhang, L. X.; Jin, J. Y.; Zhang, A. J.; Lei, X. X.; He, J. S.; Lin J. W.; Zhang H, L. Phosphorus Sulfur and Silicon, 2007, 182, 419-432.
- [17]. Mobinikhaledi, A.; Foroughifar, N.; Goli, R. Phosphorus Sulfur and Silicon, 2005, 180, 2549-2554.
- [18]. Mobinikhaledi, A.; Foroughifar, N.; Mohammadlu, P.; Kalhor, M. S. Afr. J. Chem. 2008, 61, 141-143.
- [19]. Foroughifar, N.; Mobinikhaledi, A.; Ebrahimi, Synthesis 2009, 15, 2557-2560
- [20]. Foroughifar, N.; Mobinikhaledi, A.; Ebrahimi, S.; Moghanian, H.; Bolaghi Fard, M. A.; Kalhor, M. *Tetrahedron Lett.* **2009**, *50*, 836-839. [21]. Foroughifar, N.; Mobinikhaledi, A.; Ebrahimi, S.; Bodaghi Fard, M. A.;
- Moghanian, M. J. Chin. Chem. Soc. 2009, 56, 1043-1047.
- [22]. Galic, N.; Peric, B.; Kojic-Prodic, B.; Cimerman, Z. J. Mol. Stuc. 2001, 559, 187-194.
- [23]. Wyrzykiewicz, E.; Prukah, D. J. Hetrocyclic. Chem. 1998, 35, 381-387.
- [24]. Palla, G.; Predieri, G.; Domiano, P. Tetrahedron 1986, 42, 3649-3654.